Pernix Therapeutics (PTX) Reports Q3 Loss of $2.99/Share

November 10, 2016 4:04 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($2.99), versus ($1.76) reported last year. Revenue for the quarter came in at $41.5 million, versus $48.6 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment